Botanix Pharmaceuticals Limited (BXPHF)

Market Cap	44.40M -76.9%
Revenue (ttm)	14.62M +959.2%
Net Income	-59.17M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,000
Open	0.0150
Previous Close	0.0150
Day's Range	0.0106 - 0.0150
52-Week Range	0.0100 - 0.1341
Beta	0.87
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 11
• Stock Exchange: OTCMKTS
• Ticker Symbol: BXPHF

Financial Performance

In fiscal year 2025, Botanix Pharmaceuticals's revenue was 5.79 million, an increase of 179.74% compared to the previous year's 2.07 million. Losses were -86.40 million, 522.9% more than in 2024.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error